A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia
International Journal of Hematology, 07/05/2012
Wang S et al. – The study demonstrated that recombinant human thrombopoietin (rhTPO) was well tolerated, and it markedly increased platelet counts in chronic immune thrombocytopenia (ITP) patients. Stimulation of platelet production by rhTPO may provide a new therapeutic option for patients with ITP.